WTO to Examine China’s Royalty-Setting Practices Amid Global IP Developments

The World Trade Organization (WTO) has announced plans to review China’s royalty-setting practices, a move that signals increased international oversight of the country’s intellectual property policies. This review aims to assess whether China’s royalty frameworks align with global trade and IP standards, potentially impacting licensing and enforcement strategies.

In parallel, a recent appellate court ruling concerning the trademark ‘Pisco’ has captured attention within the IP community. While details of the ruling remain specialized, the case highlights ongoing complexities in trademark law and the protection of geographical indications.

Meanwhile, the pharmaceutical sector is witnessing significant activity as Indian drug manufacturers prepare to introduce generic versions of Ozempic. This development follows the expiration of Novo Nordisk’s patent on the widely used diabetes medication, opening the market to increased competition and potentially broader access.

These stories were among the top talking points featured in the latest issue of Managing IP, which also covers a range of IP-related matters across Asia, including trademarks, copyrights, patents, and design rights.

Sukanya, who manages special projects at Managing IP such as the IP Ones to Watch and the 50 Most Influential People in IP, provides comprehensive coverage of these developments. Her expertise spans various IP domains, with a particular focus on Asian markets.

The WTO’s examination of China’s royalty-setting practices is expected to have far-reaching implications for how royalties are negotiated and enforced, affecting multinational corporations and IP holders engaged in licensing agreements with Chinese entities.

The appellate ruling on ‘Pisco’ adds to a growing body of jurisprudence concerning the protection of trademarks that are also geographical indications, a contentious area in international trademark law.

The entry of Indian generics into the Ozempic market is poised to reshape the pharmaceutical landscape by introducing more affordable options for patients, while also raising questions about patent strategy and lifecycle management for innovator companies.